Decrease in heart rate following the administration of sugammadex in adults.

ABSTRACT:

Background and aims

Sugammadex is a novel agent for reversal of steroidal neuromuscular blocking agents (NMBAs) with potential advantages over acetylcholinesterase inhibitors. In preclinical trials, there have been rare instances of bradycardia with progression to cardiac arrest. To better define this issue, its incidence and mitigating factors, we prospectively evaluated the incidence of bradycardia after sugammadex administration in adults.

Material and methods

Patients ≥ 18 years of age who received sugammadex were included in this prospective, open label trial. After administration, heart rate (HR) was continuously monitored. HR was recorded every minute for 15 minutes and then every five minutes for the next 15 minutes or until patient was transferred out of the operati

SUBMITTER: Sims T 

PROVIDER: S-EPMC8022043 | biostudies-literature | 2020 Oct-Dec

REPOSITORIES: biostudies-literature